[ Sitemap ] [ Contact ] [ Imprint ] [ News in German ]   


Related Topics:

Cancer - Molecular Basics

Current News

- Chemistry News

- Current Research Articles

- Job Market

- Chemistry Conferences

Chemistry A to Z

- Chemistry Index

- Chemicals

- Products and Companies

About Internetchemistry

- Internetchemistry

- Imprint

News in German News in German

Published: 11.08.2008 Get Internetchemistry RSS News Feed

NYU researchers demonstrate activity of mebendazole in metastatic melanoma

Novel assay finds that widely prescribed anti-parasite drug targets cancer-causing protein.

New York Researchers at the NYU Cancer Institute and the Ronald O. Perelman Department of Dermatology have identified mebendazole, a drug used globally to treat parasitic infections, as a novel investigational agent for the treatment of chemotherapy-resistant malignant melanoma.

Because most patients with metastatic melanoma fail to respond to available therapies, the discovery of a viable investigational treatment with an established safety profile could address a serious unmet need in oncology. Effectively sidestepping the prohibitive costs and long lead times typically required to discover new cancer medicines, the NYU team screened a library of already approved drugs for activity against the most deadly form of skin cancer.

Mebendazole's mechanism of action in melanoma

Mebendazole's mechanism of action in melanoma.

Image by NYU Langone Medical Center



Image by Internetchemistry

Their report, which was selected for advance online publication by Molecular Cancer Research, is published in the August issue of the journal. Since submitting the article for publication, the authors have conducted additional pre-clinical studies of mebendazole in an in vivo model of chemotherapy-resistant melanoma and are now preparing a phase I clinical trial, expected to begin next year at NYU Cancer Institute.

"While rational drug design remains a perfectly valid way to develop cancer therapies, we also need approaches that are less costly and more productive of new effective treatments," said lead author Seth J. Orlow, M.D. Ph.D., Chair of the Ronald O. Perelman Department of Dermatology at New York University School of Medicine. "You could say this is more of a guerrilla approach. Instead of screening millions of untested compounds for an agent that inhibits or stimulates a particular molecular target, we chose to screen a large library of already approved drugs for novel activity against melanoma cells, and then advance the most promising candidate rapidly to clinical practice."

First, the NYU researchers screened a library of 2,000 well-known drugs [Spectrum Collection (Microsource Discovery Systems)] and identified members of the benzimidazole family for their ability to inhibit melanoma growth and induce programmed cell death (apoptosis) of malignant melanoma cells without affecting normal melanocytes (pigment-producing cells). Of the identified benzimidazoles, the team selected mebendazole for further study because it was known to be a well-tolerated, orally available drug with anti-cancer properties.

In a surprising discovery, the team found that mebendazole takes advantage of a special difference between a melanoma cell and normal melanocytes. Melanomas produce high levels of a protein called Bcl-2, which is known to protect certain cancer cells from apoptosis. The team saw that when a melanoma cancer cell was exposed to mebendazole, it resulted in inactivation of Bcl-2, allowing apoptosis to occur.

Mebendazole, sold as a generic drug in the United States, has been used since the 1970s to treat roundworm, hookworm, pinworm, whipworm, and other worm-based parasitic infections. Previous research has shown it to have some antitumor activity in lung and adrenocortical cancer.

"Our ability to identify novel treatments for melanoma and advance them rapidly into the clinic very much depends on NYU's multidisciplinary approach to melanoma care and research," Dr. Orlow said. "To be effective, translational medicine cannot be unidirectional. Discovery moves continuously back and forth between the clinic and the bench. We are now focused on determining the range of doses to be tested in the clinic, whether specific types of melanomas will respond better than others, and whether combining mebendazole with other agents will be of further benefit".


Further Information and Source:


Nicole Doudican, Adrianna Rodriguez, Iman Osman, and Seth J. Orlow:
Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells.
In: Molecular Cancer Research; published online first on July 30, 2008; DOI: 10.1158/1541-7786.MCR-07-2159


Information about mebendazole (eMolecules no 511302)


Source: NYU Langone Medical Center / New York University School of Medicine


Related Information:


Publish your Press Release

Related topics - search form:



Internetchemistry 2007 - 2008 A. J. - last update 11.08.2008